We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02449239
Title Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Acronym VISTA
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Viventia Bio
Indications
bladder urothelial carcinoma
Therapies
Oportuzumab monatox
Age Groups: senior | adult
Covered Countries USA | CAN

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field